Compare Gilead Sciences, Inc. (GILD) vs Google Inc (GOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Google Inc — how do they compare? Gilead Sciences, Inc. trades at $148.68 (market cap $182.40B), while Google Inc trades at $347.82 (market cap $4.24T). The key difference: Google Inc is far larger — about 23.2× Gilead Sciences, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Google Inc for 137 Days on average.
| GILD | GOOG | |
|---|---|---|
Market Cap | $182.40B | $4.24T |
Volume | 4,469,821 | 13,937,902 |
Sector | Health | Media |
52-Week High | $155.80 | $399.06 |
52-Week Low | $116.74 | $237.49 |
Typical Hold Time | 111 Days | 137 Days |
Enterprise Value | $205.46B | $4.13T |
Dividend Yield | 2.23% | 0.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Alphabet (GOOG) trades at $347.37, up 0.81% with strong bullish technical signals. The company demonstrates exceptional fundamental strength with 2025 revenue of $402.84B and net income of $132.17B, maintaining robust profitability margins. Recent earnings beats and aggressive AI investments highlight growth momentum, though capital expenditure spikes have raised free cash flow concerns. Analyst consensus remains overwhelmingly positive with 87% buy ratings and a $435.24 price target.
Alphabet presents a compelling growth story with dominant market positioning and AI leadership, though investors face risks from regulatory scrutiny, intense competition, and significant capital expenditure requirements. The stock's current valuation appears reasonable relative to growth prospects, with technical indicators supporting near-term upside potential toward resistance levels around $350-352.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →
